DE69227618T2 - Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma - Google Patents

Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma

Info

Publication number
DE69227618T2
DE69227618T2 DE69227618T DE69227618T DE69227618T2 DE 69227618 T2 DE69227618 T2 DE 69227618T2 DE 69227618 T DE69227618 T DE 69227618T DE 69227618 T DE69227618 T DE 69227618T DE 69227618 T2 DE69227618 T2 DE 69227618T2
Authority
DE
Germany
Prior art keywords
elam
asthma
treatment
antibodies against
adhesion molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69227618T
Other languages
English (en)
Other versions
DE69227618D1 (de
Inventor
Robert Gundel
Craig Wegner
L Letts
C Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Baylor College of Medicine
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Baylor College of Medicine
Publication of DE69227618D1 publication Critical patent/DE69227618D1/de
Application granted granted Critical
Publication of DE69227618T2 publication Critical patent/DE69227618T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69227618T 1991-07-31 1992-07-31 Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma Expired - Fee Related DE69227618T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73863391A 1991-07-31 1991-07-31
PCT/US1992/006523 WO1993002702A1 (en) 1991-07-31 1992-07-31 Use of endothelial-leukocyte adhesion molecule-1 and antibodies thereto in the treatment of asthma

Publications (2)

Publication Number Publication Date
DE69227618D1 DE69227618D1 (de) 1998-12-24
DE69227618T2 true DE69227618T2 (de) 1999-05-06

Family

ID=24968819

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69227618T Expired - Fee Related DE69227618T2 (de) 1991-07-31 1992-07-31 Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma

Country Status (12)

Country Link
US (1) US5843441A (de)
EP (1) EP0551501B1 (de)
JP (1) JPH06502195A (de)
KR (1) KR100252621B1 (de)
AT (1) ATE173503T1 (de)
AU (1) AU663332B2 (de)
CA (1) CA2083273A1 (de)
DE (1) DE69227618T2 (de)
DK (1) DK0551501T3 (de)
ES (1) ES2123570T3 (de)
HU (1) HU215549B (de)
WO (1) WO1993002702A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5911196A (en) * 1995-06-13 1997-01-09 Nisshin Oil Mills, Ltd., The Antiasthmatic agent
US6008203A (en) * 1995-07-14 1999-12-28 Glycotech Corp. Methods for treatment of EGF receptor associated cancers
US7247302B1 (en) * 1996-08-02 2007-07-24 Bristol-Myers Squibb Company Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
AU2002308628A1 (en) * 2001-05-08 2002-11-18 Blanchette Rockefeller Neurosciences Institute Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment
MX2022009130A (es) * 2020-01-24 2022-08-22 Pfizer Anticuerpos anti-e-selectina, composiciones y metodos de uso.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927188T2 (de) * 1988-11-14 1997-04-24 Brigham & Womens Hospital Antikörper, spezifisch gegen elam-1 sowie deren verwendung
DK0387701T3 (da) * 1989-03-09 1992-12-07 Boehringer Ingelheim Pharma Anvendelse af intercellulære adhæsionsmolekyler samt deres bindende ligander ved behandling af astma
US5143712A (en) * 1990-07-30 1992-09-01 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands

Also Published As

Publication number Publication date
ATE173503T1 (de) 1998-12-15
CA2083273A1 (en) 1993-02-01
WO1993002702A1 (en) 1993-02-18
HUT69623A (en) 1995-09-28
KR930702025A (ko) 1993-09-08
HU215549B (hu) 1999-01-28
EP0551501B1 (de) 1998-11-18
KR100252621B1 (ko) 2000-09-01
ES2123570T3 (es) 1999-01-16
DK0551501T3 (da) 1999-08-02
AU2441092A (en) 1993-03-02
EP0551501A1 (de) 1993-07-21
DE69227618D1 (de) 1998-12-24
US5843441A (en) 1998-12-01
EP0551501A4 (en) 1993-09-22
AU663332B2 (en) 1995-10-05
HU9300928D0 (en) 1993-06-28
JPH06502195A (ja) 1994-03-10

Similar Documents

Publication Publication Date Title
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
DE69628912D1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ATE347565T1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
DK0627002T3 (da) Kloning og ekspression af humaniserede monoklonale antistoffer mod human interleukin-4
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
EA200200503A1 (ru) Способ лечения ревматоидного артрита
DE69229275T2 (de) Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
DE68900949D1 (de) Verfahren zur trennung von wasserstoffbehandlungs-ausfluessen.
DE69615843T2 (de) Il-8 antagonisten zur behandlung von asthma
DE69533988D1 (de) Verfahren zum blokieren von sec-rezeptoren
DE69227618D1 (de) Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma
DK0786004T3 (da) Kloning, ekspression og karakterisering af en hidtil ukendt form af phosphatidylinositol-3-kinase
ATE147406T1 (de) Synthetisches cdw52(campath-1) peptidantigen
DE69820580D1 (de) Verfahren zur Abtrennung von Metallen durch micellare Ultrafiltration, geeignet zur Behandlung von radioaktiven Abfallstoffen
ATE296316T1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung
DE3786673T2 (de) Verfahren zur entfernung unerwünschter zellen aus menschlichen lymphozytenpopulationen, anwendung des verfahrens zur herstellung monoklonaler antikörper und dafür geeigneter kit.
ATE280229T1 (de) Enterotoxine von shigella flexneri 2a
ATE317021T1 (de) Antisense modulierung von lfa-3
ATE155481T1 (de) Verfahren zur reinigung von streptolysin 0, intaktes streptolysin 0 erhältlich nach diesem verfahren und seine verwendung
DE3775182D1 (de) Monoklonale antikoerper gegen menschliche ige-rezeptoren auf lymphocyten, diese antikoerper produzierende hybridomas und reaktionsansaetze zum gebrauch dieser antikoerper.
DE59611293D1 (de) Protein mit dnase-aktivität

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee